id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-351604-x4rsdwqz	González-Gay, Miguel A.	BioLogic THERAPY IN COVID-19	2020-06-26		.txt	text/plain	1500	79	39	Taking all these considerations together and based on often preliminary data or clinical experience, physicians have used immune-modulatory treatments such as interleukin (IL)-6 and IL-1 antagonists, commonly prescribed to individuals with autoimmune and inflammatory rheumatic diseases. Recently, four patients with a confirmed diagnosis of SARS-CoV2 infection and severe pneumonia or acute respiratory distress syndrome (ARDS) have been treated with up to 4 infusions of eculizumab, an anti-complement C5a human antibody, showing all of them a marked clinical improvement within the first 48 hours after the first administration of eculizumab, including a 82-old woman with several comorbidities. In summary, based on our experience in the management of autoimmune diseases with biologic therapies and new small molecules, we strongly support the use of these agents in COVID-19 patients with severe disease or in those patients who experience a rapid deterioration due to the development of a MAS-like hyperinflammatory state. The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease	./cache/cord-351604-x4rsdwqz.txt	./txt/cord-351604-x4rsdwqz.txt